Literature DB >> 26466344

Role of rs3846662 and HMGCR alternative splicing in statin efficacy and baseline lipid levels in familial hypercholesterolemia.

Valerie Leduc1, Lucienne Bourque, Judes Poirier, Robert Dufour.   

Abstract

OBJECTIVES: To assess the contribution of the rs3846662 polymorphism of HMGCR on serum lipid levels and statin efficacy, we measured in vivo HMGCR mRNA and lipid levels in French Canadian individuals affected by heterozygous familial hypercholesterolemia due to the deletion of more than 15 kb of the LDLR gene.
RESULTS: Men and women carrying the AA genotype at rs3846662, and no APOE4 allele, had higher levels of total cholesterol (5.43 vs. 4.58 mmol/l, P<0.05) and LDL-cholesterol (5.20 vs. 4.39 mmol/l, P<0.05) at baseline. However, with regard to statin efficacy, the penetrance of the AA genotype was sex dependent. Indeed, the percentage reduction in LDL-cholesterol upon statin treatment was significantly decreased in women with the AA genotype compared with women without it (38.4 vs. 46.2%, P<0.05), whereas this was not observed in men. Although both men and women bearing the AA genotype showed a higher ratio of full-length HMGCR mRNA/total HMGCR mRNA compared with individuals without it (n=37, P<0.05), overall transcription of HMGCR was decreased and increased in men and women carrying this genotype, respectively (n=37, P<0.01 and P<0.05). Finally, in our familial hypercholesterolemia cohort, HMGCR alternative splicing explained between 22 and 55% of the variance in statin response.
CONCLUSION: rs3846662 polymorphism and the alternative splicing of HMGCR mRNA significantly impact women's response to statin therapy.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26466344      PMCID: PMC5138058          DOI: 10.1097/FPC.0000000000000178

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN: 1744-6872            Impact factor:   2.089


  54 in total

1.  A functional polymorphism in the HMGCR promoter affects transcriptional activity but not the risk for Alzheimer disease in Swedish populations.

Authors:  Lina Keller; Charlotte Murphy; Hui-Xin Wang; Laura Fratiglioni; Maria Olin; Mats Gafvels; Ingemar Björkhem; Caroline Graff; Steve Meaney
Journal:  Brain Res       Date:  2010-05-05       Impact factor: 3.252

Review 2.  Regulation of the mevalonate pathway.

Authors:  J L Goldstein; M S Brown
Journal:  Nature       Date:  1990-02-01       Impact factor: 49.962

3.  Association of the functional variant in the 3-hydroxy-3-methylglutaryl-coenzyme a reductase gene with low-density lipoprotein-cholesterol in Japanese.

Authors:  Yumiko Hiura; Yasuharu Tabara; Yoshihiro Kokubo; Tomonori Okamura; Yoichi Goto; Hiroshi Nonogi; Tetsuro Miki; Hitonobu Tomoike; Naoharu Iwai
Journal:  Circ J       Date:  2010-02-09       Impact factor: 2.993

4.  HNRNPA1 regulates HMGCR alternative splicing and modulates cellular cholesterol metabolism.

Authors:  Chi-Yi Yu; Elizabeth Theusch; Kathleen Lo; Lara M Mangravite; Devesh Naidoo; Mariya Kutilova; Marisa W Medina
Journal:  Hum Mol Genet       Date:  2013-09-02       Impact factor: 6.150

5.  Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. Effect of patient characteristics on lovastatin-induced changes in plasma concentrations of lipids and lipoproteins.

Authors:  C L Shear; F A Franklin; S Stinnett; D P Hurley; R H Bradford; A N Chremos; D T Nash; A Langendorfer
Journal:  Circulation       Date:  1992-04       Impact factor: 29.690

Review 6.  The role of HMGCR alternative splicing in statin efficacy.

Authors:  Marisa Wong Medina; Ronald M Krauss
Journal:  Trends Cardiovasc Med       Date:  2009-07       Impact factor: 6.677

7.  Intestinal cholesterol absorption efficiency in man is related to apoprotein E phenotype.

Authors:  Y A Kesäniemi; C Ehnholm; T A Miettinen
Journal:  J Clin Invest       Date:  1987-08       Impact factor: 14.808

8.  Pharmacogenetic study of statin therapy and cholesterol reduction.

Authors:  Daniel I Chasman; David Posada; Lakshman Subrahmanyan; Nancy R Cook; Vincent P Stanton; Paul M Ridker
Journal:  JAMA       Date:  2004-06-16       Impact factor: 56.272

9.  Phenotypic predictors of response to simvastatin therapy among African-Americans and Caucasians: the Cholesterol and Pharmacogenetics (CAP) Study.

Authors:  Joel A Simon; Feng Lin; Stephen B Hulley; Patricia J Blanche; David Waters; Stephen Shiboski; Jerome I Rotter; Deborah A Nickerson; Huiying Yang; Mohammed Saad; Ronald M Krauss
Journal:  Am J Cardiol       Date:  2006-01-27       Impact factor: 2.778

Review 10.  Clinical efficacy and safety of statins in managing cardiovascular risk.

Authors:  Navin K Kapur; Kiran Musunuru
Journal:  Vasc Health Risk Manag       Date:  2008
View more
  13 in total

1.  Influence of 6 genetic variants on the efficacy of statins in patients with dyslipidemia.

Authors:  Ruth Cano-Corres; Beatriz Candás-Estébanez; Ariadna Padró-Miquel; Marta Fanlo-Maresma; Xavier Pintó; Pedro Alía-Ramos
Journal:  J Clin Lab Anal       Date:  2018-05-07       Impact factor: 2.352

2.  Association study of rs3846662 with Alzheimer's disease in a population-based cohort: the Cache County Study.

Authors:  Sage M Wright; Samantha L Jensen; Kristen L Cockriel; Brian Davis; JoAnn T Tschanz; Ronald G Munger; Christopher D Corcoran; John S K Kauwe
Journal:  Neurobiol Aging       Date:  2019-03-15       Impact factor: 4.673

Review 3.  Pharmacogenomics of statins: lipid response and other outcomes in Brazilian cohorts.

Authors:  Carolina Dagli-Hernandez; Yitian Zhou; Volker Martin Lauschke; Fabiana Dalla Vecchia Genvigir; Thiago Dominguez Crespo Hirata; Mario Hiroyuki Hirata; Rosario Dominguez Crespo Hirata
Journal:  Pharmacol Rep       Date:  2021-08-17       Impact factor: 3.024

4.  Personalised medicine in hypercholesterolaemia: the role of pharmacogenetics in statin therapy.

Authors:  Najmeh Ahangari; Mohammad Doosti; Majid Ghayour Mobarhan; Amirhossein Sahebkar; Gordon A Ferns; Alireza Pasdar
Journal:  Ann Med       Date:  2020-08-24       Impact factor: 4.709

Review 5.  Pharmacogenetics of Lipid-Lowering Agents: Precision or Indecision Medicine?

Authors:  Jeffrey E Alfonsi; Robert A Hegele; Steven E Gryn
Journal:  Curr Atheroscler Rep       Date:  2016-05       Impact factor: 5.113

6.  Effects of rs3846662 Variants on HMGCR mRNA and Protein Levels and on Markers of Alzheimer's Disease Pathology.

Authors:  Valerie Leduc; Louise Théroux; Doris Dea; Robert Dufour; Judes Poirier
Journal:  J Mol Neurosci       Date:  2015-11-05       Impact factor: 3.444

Review 7.  Genetics of Familial Combined Hyperlipidemia (FCHL) Disorder: An Update.

Authors:  Eskandar Taghizadeh; Najmeh Farahani; Rajab Mardani; Forough Taheri; Hassan Taghizadeh; Seyed Mohammad Gheibihayat
Journal:  Biochem Genet       Date:  2021-09-03       Impact factor: 1.890

8.  Relationship between Lipid Phenotypes, Overweight, Lipid Lowering Drug Response and KIF6 and HMG-CoA Genotypes in a Subset of the Brisighella Heart Study Population.

Authors:  Sabrina Angelini; Martina Rosticci; Gianmichele Massimo; Muriel Musti; Gloria Ravegnini; Nicola Consolini; Giulia Sammarini; Sergio D'Addato; Elisabetta Rizzoli; Dauren Botbayev; Claudio Borghi; Giorgio Cantelli-Forti; Arrigo F Cicero; Patrizia Hrelia
Journal:  Int J Mol Sci       Date:  2017-12-24       Impact factor: 5.923

Review 9.  Pharmacogenetics of Vascular Risk Factors in Alzheimer's Disease.

Authors:  Ramón Cacabelos; Arun Meyyazhagan; Juan C Carril; Pablo Cacabelos; Óscar Teijido
Journal:  J Pers Med       Date:  2018-01-03

10.  Therapeutic targets of hypercholesterolemia: HMGCR and LDLR.

Authors:  Shizhan Ma; Wenxiu Sun; Ling Gao; Shudong Liu
Journal:  Diabetes Metab Syndr Obes       Date:  2019-08-21       Impact factor: 3.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.